This website uses cookies to enhance the user experience.
S

SERCA PHARMACEUTICALS AS921 663 846

Research
Limited company
Gaustadalléen 21 0349 OSLO, Norge

SERCA PHARMACEUTICALS AS

Keywords

researchdevelopment worknatural sciencesengineeringtechnologymedicineagricultureinterdisciplinary research

Organization

Chairman of the board
Years since formation
6 years
since Nov 7, 2018
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
717,496
1 share class
Total number of shareholders
16
8 companies, 8 persons

Financials

Total operating income 2023
3,571,688
NOK
Annual total result 2023
-4,423,990
NOK
Total equity 2023
16,391,412
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
1.51 %
indirectly

Board

NameRoleShares
Chairman-
Board Member-
Board Member-

Others

NameRoleShares
U
UNIC REVISJON AS
Auditor-
S
STATEMENT AS
Accountant-

Top 10 individual shareholders

NameRoleShares
-
4.63 %
indirectly
-
3.65 %
indirectly
-
3.1 %
indirectly
-
2.33 %
indirectly
-
2.21 %
indirectly
Managing Director/CEO
1.51 %
indirectly
-
1.51 %
indirectly
-
1.46 %
indirectly
-
1.27 %
indirectly
-
1.27 %
indirectly
Last update: Jun 7, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
S
SARSIA SEED FOND II AS
Ordinary shares
309,615
43.15 %
I
INVEN2 AS
Ordinary shares
181,400
25.28 %
M
MP PENSJON PK
Ordinary shares
63,894
8.91 %
S
SATURN INVEST AS
Ordinary shares
52,632
7.34 %
H
HERSETH AS
Ordinary shares
35,000
4.88 %
I
IFH CONSULTING AS
Ordinary shares
22,260
3.1 %
K
K OG K AS
Ordinary shares
21,630
3.01 %
Ordinary shares
7,070
0.99 %
Ordinary shares
4,880
0.68 %
Ordinary shares
4,200
0.59 %
Ordinary shares
3,640
0.51 %
Ordinary shares
3,540
0.49 %
D
Ordinary shares
2,960
0.41 %
Ordinary shares
1,755
0.24 %
Ordinary shares
1,740
0.24 %
Ordinary shares
1,280
0.18 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
3,571,688
1,984,763
2,057,459
Annual Total Result
-4,423,990
-2,795,714
-2,654,458
Total assets
17,923,659
12,568,622
17,275,207
Total liabilities
1,532,247
1,897,298
3,808,169
Total equity
16,391,412
10,671,324
13,467,038

P&L

Year202320222021
Total operating income
3,571,688
1,984,763
2,057,459
Total operating costs
7,992,931
4,734,155
4,720,256
Operating result
-4,421,243
-2,749,392
-2,662,797
Financial income/costs
-2,747
-46,323
8,339
Profit before tax
-4,423,990
-2,795,714
-2,654,458
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-4,423,990
-2,795,714
-2,654,458

Balance overview

Year202320222021
Total fixed assets
0
0
0
Total current assets
17,923,659
12,568,622
17,275,207
Total assets
17,923,659
12,568,622
17,275,207
Short term debt
1,532,247
1,897,298
3,808,169
Long term debt
0
0
0
Total liabilities
1,532,247
1,897,298
3,808,169
Contributed capital
20,815,402
10,671,324
13,467,038
Retained earnings
-4,423,990
0
0
Total equity
16,391,412
10,671,324
13,467,038
Total equity and liabilities
17,923,659
12,568,622
17,275,207

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.19
Industrial group
Other research and experimental development on natural sciences and engineering
72.190
Industrial group
Other research and experimental development on natural sciences and engineering